Skip to main content

TTD STOCK WRITE UP


TTD (THE TRADE DESK)

  • P/E: 54.58
  • GAAP DILUTED Y-O-Y EPS GROWTH LAST QUARTER: $.11
  • SECTOR: COMMERCIAL SERVICES
  • ASSETS-LIABILITIES: 1.44
  • DIVIDEND: none

The Trade Desk, or TTD, is an online advertising company. TTD also hosts an online advertising marketplace. The industry for this company is rapidly expanding, and it currently has the highest percentage of market share by a large margin.
In the most recent quarter, TTD increased revenue 70% year-over-year. Operating expenses also grew across the board, as the company nearly doubled its spending on sales, marketing, technology and development (the company does not track R&D), general/administrative costs, and “platform operations,” bringing the gross margin down slightly. Prior to the implementation of GAAP, TTD posted a $.05 gain in EPS, and $.11 afterward. The company reduced its debt, and doubled its assets from the last comparable quarter. Most of the increase in assets is located in the company's enormous cash pile.
Jeff Green, who founded the company in 2009, also serves as its CEO. Previously, he founded AdECN, which the company boasts as the world's first online advertising exchange. The company specializes in marketing on digitally broadcast TV shows and other videos, digital audio such as Spotify, social media and other digital platform advertising, and hosting a marketplace where advertisers can bid on advertising space in real-time based on metrics which the company also provides. Similartech rates TTD as the largest provider of online advertising. Although the company already has the bulk of the market share in its burgeoning space, its revenue has been growing exponentially due to the expansion of the online advertising space. As online media becomes more popular, so do the advertising services catering to these markets.
Despite its cash pile, the company recently completed a second offering to raise funds in March 2017. For the upcoming quarter, TTD has given a guidance of $43 million revenue, slightly below Wall Street's expectation of $43.42 million. Wall Street is expecting $.01 EPS, an improvement over the loss in the comparable Q1 '16, but still down from Q1 '15. On its press release, the company announces its goal as aggressive investing rather than extracting profits, and an analysis of revenue growth reveals that revenue on a quarterly basis has doubled from the Q1 '15 quarter.
TTD has committed itself to aggressive investment within a burgeoning industry, focusing on revenue rather than profits. Its stock trades at a high price-to-earnings multiple because of the high expectations for revenue growth. In the past, the company has shown rapid revenue growth. With the company reporting on 5/11/17, Wall Street will be looking for the company to deliver on its promise of revenue growth to propel the stock further upward.





Labels:

Comments

Post a Comment

Popular posts from this blog

ISRG STOCK WRITE UP

ISRG (INTUITIVE SURGICAL INC) P/E: 48 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $1.13 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 7.05 DIVIDEND: none ISRG is the ticker for Intuitive Surgical Inc, a company endeavoring in the manufacture and distribution of robotic surgical devices. The company recently gained FDA approval for a lower-cost device. They have a clean balance sheet with a history of upside surprises against earnings expectations, and report again 7/20/17. Revenues increased nearly 14%, while EPS increased 32% compared to the Q1 '16 results. While liabilities decreased on a year-over-year basis, assets decreased by a larger margin. R&D spending increased 36%, and administrative costs rose 16%. Taxes were cut in half, although the revenues increased, due to modified accounting principles, and tax benefits for the employee share-based compensation.. The ratio of assets-liabilities decreased from 9.14 to 7.05, which is...
1 comment
Read more

AMGN STOCK WRITE UP

AMGN P/E: 16.1 GAAP EPS Y-O-Y GROWTH LAST QUARTER: $.22 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.62 DIVIDEND: 2.54% Amgen is a leading biotech company with a solid financial foundation. It has managed to reduce its spending on research and development while increasing revenue through its sales of established drugs such as Enbrel, and Prolia. The company has several rapidly growing drugs that are newer to the market, with many drugs in the company's pipeline. In its last quarter, Amgen posted 7.7% revenue growth with 7.5% net income growth. The company spent less, however, in the most recent quarter when compared with the comparable quarter from the prior year, on research and development. The reduction in operating margin came from an increased interest expense in the quarter. Although the company spent less on research and development, its revenue did increase. Amgen is continuing to innovate despite reduced research and development b...
Post a Comment
Read more

PXD STOCK WRITE UP

 PXD (PIONEER NATURAL RESOURCES) P/E: N/A GAAP DILUTED Y-O-Y EPS GROWTH LAST QUARTER: $.67 SECTOR: ENERGY MINERALS ASSETS-LIABILITIES: 1.58 DIVIDEND: .04% Pioneer Natural Resources has recently made the jaw-dropping switch from negative EPS to positive with its last quarter. Situated in the largest oil-producing region in the US, the company is utilizing its good fortune to produce profits. The company has a good balance sheet, a wealth of resources, and a business model which has afforded it growth. This last quarter does not mark the first occasion on which Pioneer has posted a profit. In 2014, and 2012, Pioneer posted a positive EPS for the full year. While the 2016 oil and gas revenues have grown from 2015, the 2014 and 2012 levels were higher. The company's revenue from oil and gas is largely based on market prices. In order to mitigate the market volatility, Pioneer has made efforts to reduce their cost of production, according to their earnin...
1 comment
Read more